艾曲泊帕联合标准免疫抑制治疗初治重型再生障碍性贫血:RACE研究2年最终分析
RACE研究为前瞻性随机III期优效性试验,比较hATG+CsA±艾曲泊帕一线治疗初治重型再生障碍性贫血。
要点
- 艾曲泊帕联合标准IST显著提高2年完全缓解率(62.4% vs 35.3%)。
- 联合组2年无病生存和事件无生存均显著优于标准IST组。
- 联合组未增加克隆演变或继发髓系恶性肿瘤风险。
核心结论
- 初治重型再生障碍性贫血中,艾曲泊帕联合标准IST的早期血液学缓解优势转化为更好的2年OS、DFS和EFS,且不增加继发髓系肿瘤风险。
研究设计与样本
- 患者随机接受标准IST(hATG 40 mg/kg×4天+CsA 5 mg/kg/天;A组n=101)或标准IST+艾曲泊帕150 mg/天(B组n=96),艾曲泊帕从第+14天至6个月(完全缓解者用3个月)。
- 中位随访23.2个月。
主要发现
- 2年完全缓解累积发生率B组显著优于A组(62.4% vs 35.3%;p<0.001)。
- 2年总生存率A组86%、B组91%(p=0.081),年龄和疾病严重度校正后HR=0.54(p=0.064)。
- 2年无病生存率B组56% vs A组37%(校正HR=0.49;p<0.001),事件无生存率B组48% vs A组32%(校正HR=0.54;p<0.001),均显著优于A组。
- 两组复发累积发生率相当;演变为临床阵发性睡眠性血红蛋白尿A组8%、B组1%(p=0.041)。
- 克隆演变风险低,A组1例、B组2例出现核型异常。
临床怎么用
- 对初治重型再生障碍性贫血,可考虑在标准IST基础上加用艾曲泊帕150 mg/天(从第+14天至6个月)以提高完全缓解率和2年DFS/EFS。
- 治疗决策时需结合年龄和疾病严重度评估,并监测克隆演变。
局限性
- 2年OS差异未达统计学显著(p=0.081)。
- 随访时间有限(中位23.2个月),长期克隆演变风险需更长期观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2-year analysis of this prospective randomized phase III study. One hundred ninety-seven treatment-naive patients were randomized to standard IST (hATG 40 mg/kg × 4 days and CsA 5 mg/kg/day; arm A; n = 101) or standard IST + eltrombopag at the dose of 150 mg/day (arm B; n = 96) from day +14 until 6 months (or 3 months, in case of complete response). The median follow-up was 23.2 months. The 2-year cumulative incidence of complete response was significantly superior in arm B (62.4% vs. 35.3%; p < 0.001). The 2-year overall survival (OS) was 86% in arm A and 91% in arm B (p = 0.081), with hazard ratio (HR), adjusted for age and disease severity, of 0.54 (p = 0.064). The 2-year disease-free survival (DFS) was 56% vs. 37% (adjusted HR = 0.49; p < 0.001), while event-free survival (EFS) was 48% vs. 32% (p < 0.001), with adjusted HR = 0.54 (p < 0.001), both significantly superior for arm B. The cumulative incidence of relapse was comparable in the two arms, while evolution to clinical paroxysmal nocturnal hemoglobinuria was 8% in arm A and 1% in arm B (p = 0.041). The risk of clonal evolution remained negligible, with one patient in arm A and two in arm B developing karyotypic abnormalities. The initial hematological response benefit of eltrombopag added to IST as front-line treatment of AA is associated with better 2-year OS, DFS, and EFS without increased risk of secondary myeloid malignancies.
引用
- Risitano AM, Iacobelli S, Kulasekararaj A, et al. Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. Am J Hematol. 2026. PMID: 42472670. doi:10.1002/ajh.70445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。